• Azathramycin A: Mechanistic Advances in Macrolide Antibiotic

  2026-07-09

  Explore the unique molecular action of Azathramycin A, a macrolide antibiotic, and its implications for tuberculosis resistance modeling and assay design. This article delves deeper than protocol guides, offering mechanistic insights and practical applications for advanced antibacterial research.

• CD40–STING Competition Drives IRF4+ B Cell Activation in ESC

  2026-07-08

  The referenced study elucidates how competitive binding between CD40 and STING with TRAF2 regulates IRF4-mediated B cell activation within tertiary lymphoid structures (TLS) in esophageal squamous cell carcinoma (ESCC). This mechanistic insight links TLS abundance to favorable prognosis and highlights new avenues for biomarker and therapeutic development in ESCC.

• VX-661: Optimizing F508del CFTR Correction for Cystic Fibros

  2026-07-08

  VX-661 (F508del CFTR corrector) enables precise restoration of CFTR trafficking in advanced cystic fibrosis models, with robust, variant-specific workflows informed by calnexin-dependent modulation. This article unpacks stepwise protocols, troubleshooting strategies, and actionable insights, helping researchers maximize CFTR rescue and functional recovery.

• CHIR 99021 Trihydrochloride: Unveiling GSK-3 Inhibition for

  2026-07-07

  Explore how CHIR 99021 trihydrochloride, a potent GSK-3 inhibitor, empowers tunable control of stem cell self-renewal and differentiation in human organoid systems. This article delivers new insights into optimizing cellular diversity and scalability, advancing beyond conventional protocols.

• Anti-Fibrotic Actions of 1-Phenyl-2-Pentanol in Hepatic Stel

  2026-07-07

  This study identifies 1-phenyl-2-pentanol (1-PHE) from Moringa oleifera as a potent inhibitor of hepatic stellate cell activation and fibrosis markers in vitro. Through multi-omic profiling, the paper uncovers 1-PHE's modulation of TGF-β1 and Wnt/β-catenin signaling, providing mechanistic insight with translational implications for liver fibrosis research.

• Taltirelin Attenuates Acute and Chronic Itch in Mouse Models

  2026-07-06

  A recent study demonstrates that Taltirelin, a long-acting TRH analog, significantly reduces both acute and chronic itch behaviors in mice. This work establishes Taltirelin as a promising research tool for dissecting neuroendocrine modulation of pruritus and supports its translational potential in antipruritic drug development.

• Palmitic acid (Hexadecanoic Acid): Technical Use and Protoco

  2026-07-06

  Palmitic acid (hexadecanoic acid, SKU N2456) addresses the need for a high-purity, well-characterized saturated long-chain fatty acid in research focused on lipid metabolism, protein palmitoylation, and metabolic disorder pathways. It is unsuitable for aqueous-based protocols or workflows requiring prolonged solution stability, so precise handling and preparation are critical to ensure reproducible results.

• Coronavirus Macrodomains Counteract PARP-Mediated Antiviral

  2026-07-05

  Grunewald et al. (2019) uncovered that the coronavirus macrodomain is essential for evading poly (ADP-ribose) polymerase (PARP)-mediated inhibition of viral replication and for limiting interferon production, highlighting the pivotal roles of PARP12 and PARP14 in innate immunity. This work clarifies the molecular interplay between viral macrodomains and host ADP-ribosylation, suggesting new directions for antiviral research and pharmacological targeting.

• MK-2206 dihydrochloride: Unraveling Akt Pathway Suppression

  2026-07-04

  Explore how MK-2206 dihydrochloride, a selective Akt inhibitor, advances research into PI3K/Akt/mTOR signaling, persistent infection, and cancer cell apoptosis. This article uniquely bridges molecular immunology and oncology, revealing assay decisions that stem from the latest mechanistic insights.

• Caffeine (1,3,7-trimethylpurine-2,6-dione) in Cancer and Met

  2026-07-03

  Caffeine’s dual role as an adenosine receptor antagonist and metabolic regulator makes it an indispensable reagent in cancer and obesity research. This article delivers actionable protocols, advanced troubleshooting, and novel insights on leveraging APExBIO’s Caffeine N2379 for robust, reproducible results across in vitro and in vivo systems.

• Surface Chemistry of Magnetite–CNCs: Cytocompatibility & Hyp

  2026-07-03

  This study systematically reveals how surface chemistry of cellulose nanocrystals (CNCs) governs the assembly, magnetic properties, and cytocompatibility of magnetite-based nanocomposites for hyperthermia applications. By elucidating molecular interactions and quantifying heating efficiency, it provides a framework for rational design of safe, biocompatible nanomaterials in biomedical research.

• Universal nPEC Method for Dual-Loaded Liposome Encapsulation

  2026-07-02

  This study introduces a validated nanoparticle exclusion chromatography (nPEC) method for accurately determining the encapsulation efficiency of both hydrophilic and lipophilic drugs in dual-loaded liposomes. Its universal applicability addresses a longstanding analytical challenge, supporting advanced drug delivery and combinatorial therapeutic research.

• Gene Expression Predictors of Olaparib Response in Mesotheli

  2026-07-02

  Borchert et al. (2019) identified homologous recombination repair (HRR) defects—termed 'BRCAness'—in malignant pleural mesothelioma (MPM) that predict enhanced susceptibility to PARP inhibitor (olaparib) therapy, especially in BAP1-mutated lines. Their gene expression profiling establishes new prognostic markers and suggests that targeted therapeutic combinations could improve clinical outcomes for specific MPM subgroups.

• Bazedoxifene: Beyond Osteoporosis—Targeting IL-6/GP130 Signa

  2026-07-01

  Explore Bazedoxifene, a selective estrogen receptor modulator, as a dual-purpose tool in postmenopausal osteoporosis and IL-6/GP130 pathway research. Uncover its unique mechanistic roles, protocol strategies, and the latest translational insights linking estrogen signaling to emerging oncology applications.

• Advancing Drug Response Evaluation: Insights from In Vitro O

  2026-07-01

  Schwartz's dissertation introduces a rigorous framework for distinguishing between drug-induced proliferation arrest and cell death in cancer in vitro models. By systematically comparing relative and fractional viability metrics, the study clarifies key aspects of anti-cancer drug responses and offers refined protocols for interpreting in vitro results—supporting improved translational relevance in oncology drug discovery.

453 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page